TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02061267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polyunsaturated meal
Description: Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
Study: NCT01785446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Consumption of cisatracurium and sufentanil in different age groups.
Description: For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
Study: NCT03489720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed Exercise Program
Description: Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prescribed Exercise Program
Description: Brief cardiovascular exercise training (\>70% of maximum heart rate) for 15 minutes a day, 5 days a week for 8 weeks.~The exercise intervention will be a 15-minute per day of vigorous exercise that as monitored by a Fitbit Charge 2.~Examples of possible 15-minute exercise regimens to be used include:~* Walking quickly or running up and down stairs~* Plyometric exercises such as jumping jacks, high knees, squats, lunges, speed skaters, froggers, etc~* Walking up an incline on a treadmill~* Jogging or running on a treadmill or elliptical~* Stationary cycling or rowing
Study: NCT03440996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinpro™ 5000
Description: Clinpro™ 5000 with 1.1% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinpro™ Tooth Crème
Description: Clinpro™ Tooth Crème with 0.21% Sodium Fluoride is a new anti-cavity toothpaste, and is currently available and have been shown in some initial case reports to be useful in the reduction of white spot lesions. Clinpro™ restores minerals and helps you produce saliva. The Clinpro™ products are advanced formulas containing an innovative tri-calcium phosphate ingredient. It is available exclusively from 3M ESPE. Clinpro™ contains fluoride as well as calcium and phosphate, which are components naturally found in saliva.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MI-Paste Plus
Description: MI-Paste Plus is a widely used anti-cavity toothpaste on the market and it is used as a control group in this study.
Study: NCT02262299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Receive tablets with pirfenidone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Recieve tablets with placebo
Study: NCT04217694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogstate Assessment Battery
Description: Complete CogState testing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride
Description: Given PO
Study: NCT03489720

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Exercise Program
Description: Usual exercise activity for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Exercise Program
Description: Usual exercise activity for 8 weeks
Study: NCT05254067

Intervention type: DEVICE
Intervention: Codman Enterprise 2 Vascular Reconstruction Device
Description: a self-expanding nitinol, compliant, closed-cell, recapturable design that can be deployed by a single operator designed to assist in the stent-assisted coil embolization of intracranial aneurysms, specifically those that have a wide neck that would not otherwise maintain the coil embolization material within the aneurysm because of the wide opening at the base of the aneurysm.
Study: NCT01470300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy density feeding study
Description: In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit \& vegetables, decreased fat, added plain water).
Study: NCT06455488

Intervention type: PROCEDURE
Intervention: Ventricular Tachycardia Ablation
Description: This is a surgical ablation meant to reset patients irregular rhythm back to sinus.

Intervention type: DEVICE
Intervention: ICD Implant
Description: A pacemaker or defibrillator implant to prevent SCD

Intervention type: DRUG
Intervention: Antiarrhythmic drug
Description: Drug therapies

Intervention type: DIAGNOSTIC_TEST
Intervention: EKG
Description: Monitoring EKG testing done on registry patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardioversion
Description: Monitoring cardioversions on registry patients

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiogram
Description: Monitoring echocardiogram testing done on patients
Study: NCT00767741

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: with heat and massage
Description: For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
Study: NCT00514306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
Study: NCT03637296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Critical time intervention
Description: Care management offered by individual with experience working with individuals with serious mental illness. The care managers engage individuals before they are discharged from the hospital and work with them in the community to support linkages with medical and behavioral health care providers. Care managers provide problem-solving, advice, and support to maximize patients' engagement in care.
Study: NCT03134300

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Cytokine from blood
Description: Blood draw- one intraoperative, one 3 weeks postoperative

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Cytokine from blood
Description: Blood draw- one intraoperative, one 3 weeks postoperative
Study: NCT00837954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyostypt® AND Surgicel®
Description: The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyostypt® AND Surgicel®
Description: The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lyostypt®
Description: The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.~Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgicel®
Description: The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.~Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage.
Study: NCT04114019

Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal tactile imager
Description: Vaginal elasticity evaluation using a vaginal tactile imager
Study: NCT01078909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Study: NCT05789147

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tVNS
Description: It is a non-invasive transcutaneous electrical stimulation of the auricular branch of the vagus nerve which innervates the skin of the human ear. These nerve fibers project directly to the solitary tract nucleus (NTS) in the brain stem (6).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tVNS
Description: Sham stimulation is obtained by placing the stimulation electrode at the level of the earlobe. The stimulation is therefore administered and perceived in an area not innervated by vagal fibers.
Study: NCT02573441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jump Math
Description: Jump Math is a workbook based program aimed at improving math skills

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed
Description: Cogmed is an online computer program aimed at improving working memory skills

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Liaison Services
Description: Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liaison Services
Description: Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liaison Services
Description: Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
Study: NCT02287818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration \<6 mg/dL
Study: NCT01844466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy and speech therapy
Study: NCT05864963

Intervention type: PROCEDURE
Intervention: Medial tab-type fasciocutaneous flap
Description: The flap can be taken in different ways depending on the defect. Once the base of the flap is identified, the posterior edge of the tibia is taken as reference; marking of the tab is performed considering that the posterior incision is located 5 cm from the posterior edge of the tibia, and the anterior incision is located longitudinally of the medial region of the tibial diaphysis, the length of the incision depends on the base of the flap and the defect's size.~The posterior incision is made first in the skin, subcutaneous cellular tissue until the fascia is identified; the subfascial flap is dissected to avoid injuring perforators, dissection is completed up to the anterior edge of the flap, if needed direct cutaneous perforators are ligated; once the subfascial plane has been identified and dissected, the tab is completed in its proximal or distal part according to the previous surgical planning. Later, the tab is rotated to the anterior region of the tibia to cover the defect.
Study: NCT02345265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given PO
Study: NCT01397110

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory and exercise therapy
Description: Conventional therapy with specific respiratory and physical therapy plus mental walking training
Study: NCT01121848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Study: NCT02345265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo echocardiogram

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01450696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered at a dose of 800 mg/m\^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
Study: NCT01121848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV~Dose regimen:
Study: NCT03398135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection
Study: NCT01516931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: counseling
Description: Placebo monthly by general counseling for 12 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: counseling
Description: Placebo monthly by general counseling for 12 months.
Study: NCT01138553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 200mg capsules daily for 5-28 days
Study: NCT03780907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007
Description: 1 mg of E2007 was administered by mouth once daily.
Study: NCT03398135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: subcutaneous (SC) injection
Study: NCT03775096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: At the end of Baseline visit, carvedilol 3.125 twice daily will be initiated and maintained for 1 week, increased to 6.25twice daily (dispensed at week 1visit), to 12.5mg twice daily (dispensed at week 2) and a max dose of 25mg twice daily (dispensed at week 4 visit), as tolerated. A subject that cannot tolerate at least a 25 mg daily dose will be excluded from the study. Subjects that cannot tolerate the 50 mg daily dose, will be offered to continue at the 25 mg daily dose. The project will include a washout period at study end.
Study: NCT02997228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study: NCT01078909

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)
Description: Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
Study: NCT02997228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or CT/PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or CT/PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or CT/PET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo CT/PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo CT/PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo CT/PET

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies